Trial reportJournal of neuro-oncology2018
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
1.9field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Charged particle therapy for high-grade gliomas in adults: a systematic review.Radiation oncology (London, England) · 2023Pooled it
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.Journal of neuro-oncology · 2020Pooled it
- External beam radiation dose escalation for high grade glioma.The Cochrane database of systematic reviews · 2020Pooled it
- Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.The Cochrane database of systematic reviews · 2019Pooled it
- Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma.Journal of healthcare engineering · 2022Trial
- The evolution of RTOG and NRG Oncology CNS tumors clinical trials.Journal of neuro-oncology · 2026Review
- Radiotherapeutic advances in the management of glioblastoma.Journal of neuro-oncology · 2024Review
- Carbon-ion radiotherapy alone vs. standard dose photon radiation with carbon-ion radiotherapy boost for high-grade gliomas: a retrospective study.BMC cancer · 2024Article
- Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Initiatives Toward Clinical Boron Neutron Capture Therapy in Japan.Cancer biotherapy & radiopharmaceuticals · 2023Article
- Gene Therapy for High Grade Glioma: The Clinical Experience.Expert opinion on biological therapy · 2023Review
- Surgically targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review.Neuro-oncology · 2022Review
- Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy.Journal of clinical medicine · 2022Review
- Multi-Planar VMAT Plans for High-Grade Glioma and Glioblastoma Targeting the Hypothalamic-Pituitary Axis Sparing.Life (Basel, Switzerland) · 2022Article
- Glioblastoma - treatment and obstacles.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Review
- Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.Journal of neuro-oncology · 2022Article
- Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields.Journal of Cancer · 2021Review
- Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.Radiation oncology (London, England) · 2019Article
- Influence of 3D-CRT and conformal IMRT on thyroid function of patients with cervical and upper thoracic esophageal cancer and comparison of clinical efficacy.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 1 country.
Arif N AliEmory University/Winship Cancer Institute, 1365 Clifton Rd NE, Atlanta, GA, 30322, USA. aali24@emory.edu.ORCID http://orcid.org/0000-0003-3860-1242
Peixin ZhangNRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
W K Alfred YungThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yuhchyau ChenUniversity of Rochester Medical Center, Rochester, NY, USA.
Benjamin MovsasHenry Ford Hospital accruals Fox Chase Cancer Center, Detroit, MI, USA.
Raul C UrtasunCross Cancer Institute, Edmonton, AB, Canada.
Christopher U JonesSutter General Hospital accruals Radiological Associates of Sacramento, Sacramento, CA, USA.
Kwang N ChoiState University of New York Downstate Medical Center, Brooklyn, NY, USA.
Jeff M MichalskiWashington University School of Medicine, St. Louis, MO, USA.
A Jennifer FischbachIntermountain Medical Center accruals LDS Hospital, Murray, UT, USA.
Arnold M MarkoeSylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Christopher J SchultzFroedtert and the Medical College of Wisconsin, Milwaukee, WI, USA.
Marta Penas-PradoThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Madhur K GargMontefiore Medical Center, Moses Campus, Bronx, NY, USA.
Alan C HartfordDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Harold E KimWayne State University, Detroit, MI, USA.
Minhee WonNRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
Walter J CurranEmory University/Winship Cancer Institute, 1365 Clifton Rd NE, Atlanta, GA, 30322, USA.
NRG Oncology · USThe University of Texas MD Anderson Cancer Center · USDartmouth–Hitchcock Medical Center · USEmory Healthcare · USEmory University · USFox Chase Cancer Center · USFroedtert Hospital · USLDS Hospital · USMontefiore Medical Center · USState University of New York · USSutter Medical Center · USUniversity of Miami · USUniversity of Rochester Medical Center · USWashington University in St. Louis · USWayne State University · US
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MRTOG Foreign AccrualU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI CURRAN, WALTER J. · 1985 to 2013
$150.3MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4MNRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5MTumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Jennifer L Beebe-Dimmer · 1985 to 2026
$68.4MRTOG Foreign AccrualsU10CA037422 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI BRUNER, DEBORAH WATKINS · 1985 to 2013
$30.4MNational Cancer Institute U10CA180822National Cancer Institute U10CA180868National Cancer Institute U10CA21661National Cancer Institute U10CA37422NCI NIH HHS P30 CA022453NCI NIH HHS U10 CA021661NCI NIH HHS U10 CA037422NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189867
Abstract
From 1990 to 1994, patients with newly diagnosed malignant gliomas were enrolled and randomized between hyperfractionated radiation (HFX) of 72.0 Gy in 60 fractions given twice daily and 60.0 Gy in 30 fractions given once daily. All patients received 80 mg/m
Indexed as
Dose Fractionation, RadiationAdolescentAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingBrain NeoplasmsCarmustineCombined Modality TherapyFemaleGliomaHumansMaleMiddle AgedSurvival AnalysisTreatment OutcomeAntineoplastic Agents, AlkylatingCarmustineAstrocytomaGBMGliomaHyperfractionatedOligodendroglioma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.